Ascend Capital’s Array Biopharma Inc ARRY Stock Holding History

Ascend Capital’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-200,000	Closed	-$1.35M	–	188
2016 Q3	$1.35M	Buy	+200,000	New	+$774K	0.08%	103

Other funds holding ARRY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Ascend Capital's ARRY Position: Q4 2016 in Review

Ascend Capital sold out of Array Biopharma Inc (ARRY) in Q4 2016, closing a stake of 200,000 shares — an estimated $1.35M sold.

Ascend Capital first reported a position in ARRY in Q3 2016 and held it in 1 quarter. The position peaked at $1.35M in Q3 2016. 167 funds tracked by Wall St. Rank hold ARRY as of Q4 2016.

Ascend Capital reported no remaining Array Biopharma Inc position as of Q4 2016 after selling out during the quarter.
Ascend Capital sold 200,000 Array Biopharma Inc shares in Q4 2016, an estimated $1.35M.
Ascend Capital first reported a position in Array Biopharma Inc in Q3 2016 and held it in 1 quarter.
Ascend Capital's Array Biopharma Inc position peaked at $1.35M in Q3 2016.
167 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q4 2016.

Based on Ascend Capital's 13F filing for Q4 2016, filed 13 Feb 2017.